2. Search Result
Search Result
Results for "

CYP

" in MedChemExpress (MCE) Product Catalog:

1171

Inhibitors & Agonists

1

Screening Libraries

10

Fluorescent Dye

4

Biochemical Assay Reagents

4

Peptides

1

MCE Kits

189

Natural
Products

16

Recombinant Proteins

132

Isotope-Labeled Compounds

48

Antibodies

6

Click Chemistry

89

Oligonucleotides

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-18642
    CYP3cide

    PF-4981517

    		 Cytochrome P450 Others
    CYP3cide (PF-4981517) is a potent, selective and time-dependent inhibitor of cytochrome P4503A4 (CYP3A4). The IC50 values for Midazolam 1’-hydroxylase activity are 0.03 μM, 17 μM, and 71 μM for CYP3A4, CYP3A5, and CYP3A7, respectively. CYP3cide can be used to distinguish the contributions of CYP3A4 versus CYP3A5 on agent metabolism .
    CYP3cide
  • HY-152118
    CYP1B1-IN-4

    		Cytochrome P450 Cancer
    CYP1B1-IN-4 is a 2,4-diarylthiazole compound with selectively CYP1B1 inhibition (IC50=0.2 nM). CYP1B1-IN-4 has little cytotoxicity and high stability in both human and rat liver microsomes .
    CYP1B1-IN-4
  • HY-156530
    CYP11A1-IN-1

    		Cytochrome P450 Endocrinology
    CYP11A1-IN-1 (compound 30) is an inhibitor of CYP11A1, with IC50 value of 201-2000 nM. CYP11A1-IN-1 can be used for research in steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer .
    CYP11A1-IN-1
  • HY-W072025
    CYP2E1-IN-1

    		Cytochrome P450 Keap1-Nrf2 Heme Oxygenase (HO) Reactive Oxygen Species (ROS) Inflammation/Immunology
    CYP2E1-IN-1 (Compound 10) is an orally active cytochrome P450 2E1 (CYP2E1) inhibitor with a Kd of 7.02 μM, an IC50 of 1.64 μM, and a Ki of 0.897 μM. CYP2E1-IN-1 activates the Nrf2/HO-1 signaling pathway and inhibits ROS production, thereby alleviating pancreatic injury. CYP2E1-IN-1 has significant anti-inflammatory and antioxidant activities and can effectively reduce inflammation and oxidative stress in severe acute pancreatitis (SAP). CYP2E1-IN-1 can be used in the study of SAP and other inflammatory-related diseases .
    CYP2E1-IN-1
  • HY-120377
    CYP1A1 inhibitor 8a

    		HBV Cancer
    CYP1A1 inhibitor 8a is a compound that potently and selectively inhibits the CYP1A1 enzyme and has the potential to prevent cancer. CYP1A1 inhibitor 8a exhibits more than 10-fold selectivity for CYP1A1 and more than 100-fold selectivity over other enzymes in the CYP1 subfamily. CYP1A1 inhibitor 8a can effectively antagonize B[a]P-mediated activation of the aryl hydrocarbon receptor (AhR) in yeast cells and protect human cells from CYP1A1-mediated B[a]P toxicity. CYP1A1 inhibitor 8a has the potential to be developed as a cancer chemopreventive agent .
    CYP1A1 inhibitor 8a
  • HY-157942
    CYP1B1-IN-7

    		Cytochrome P450 Cancer
    CYP1B1-IN-7 (compound 2a) is a selective inhibitor of CYP1B1 (IC50: 75 nM). CYP1B1-IN-7 also reverses resistance (IC50: 29 μM) and exhibits cytotoxicity in the CYP1B1-overexpressing MCF-7 cell line that is resistant to Docetaxel (HY-B0011) .
    CYP1B1-IN-7
  • HY-150775
    CYP19A1-IN-2

    		Cytochrome P450 Cancer
    CYP19A1-IN-2 (Compound 13h) is a nonsteroidal aromatase (CYP19A1) inhibitor (IC50=0.09 nM). CYP19A1-IN-2 has potential for breast cancer research . CYP19A1-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    CYP19A1-IN-2
  • HY-152159
    CYP4Z1-IN-1

    		Cytochrome P450 Cancer
    CYP4Z1-IN-1 (compound 7c) is a potent CYP4Z1 inhibitor, with an IC50 of 41.8 nM. CYP4Z1-IN-1 decreases the expression of breast CSCs stemness markers, spheroid formation, and metastatic ability as well as tumor-initiation capability in a concentration-dependent manner in vitro and in vivo .
    CYP4Z1-IN-1
  • HY-150574
    CYP3A4-IN-1

    		Cytochrome P450 Infection
    CYP3A4-IN-1 (compound 5a) is a potent cytochrome P450 3A4 (CYP3A4) inhibitor with an IC50 value of 0.085 µM .
    CYP3A4-IN-1
  • HY-159006
    CYP1B1 ligand 3

    		Cytochrome P450 Cancer
    CYP1B1 ligand 3 (Compound A1) is a selective inhibitor for cytochrome P450 enzyme CYP1B1 with an IC50 of 11.9 nM. CYP1B1 ligand 3 can be utilized for the synthesis of PROTAC CYP1B1 degrader-2 (HY-158429) .
    CYP1B1 ligand 3
  • HY-151809
    CYP4A11/CYP4F2-IN-1

    		Cytochrome P450 Metabolic Disease
    CYP4A11/CYP4F2-IN-1 is a potent dual inhibitor of cytochrome P450 (CYP) 4A11 and CYP4F2, with IC50s of 19 nM and 17 nM, respectively. CYP4A11/CYP4F2-IN-1 has potential for the research of renal diseases .
    CYP4A11/CYP4F2-IN-1
  • HY-W082430
    CYP2A6-IN-2

    		Cytochrome P450 Neurological Disease
    CYP2A6-IN-2 (compound 5) is a CYP2A6 inhibitor. CYP2A6-IN-2 can be used in the study of nicotine dependence .
    CYP2A6-IN-2
  • HY-151251
    CYP2C9/CYP2C19-IN-1

    		Cytochrome P450 Virus Protease Infection
    CYP2C9/CYP2C19-IN-1 (compound 22d) is a potent CYP2C9/CYP2C19 inhibitor, possessing no hepatotoxicity and ames toxicity. CYP2C9/CYP2C19-IN-1 can be used in study of anti-ZIKV .
    CYP2C9/CYP2C19-IN-1
  • HY-179138
    CYP51-IN-28

    		Cytochrome P450 Fungal Infection
    CYP51-IN-28 (compound B9) is a CYP51 inhibitor. CYP51-IN-28 is an efficient, broad-spectrum, and low toxicity antifungal molecule. CYP51-IN-28 can be used for research on fungal infections .
    CYP51-IN-28
  • HY-178162
    CYP51-IN-27

    		Fungal Cytochrome P450 Infection
    CYP51-IN-27 is a sterol 14α-demethylase CYP51 inhibitor with an IC50 of 0.3434 μg/mL. CYP51-IN-27 exhibits antifungal activity and inhibits the production of fungal ergosterol. CYP51-IN-27 can be used for the research of infection, such as rice sheath blight .
    CYP51-IN-27
  • HY-157170
    CYP450-IN-1

    		Cytochrome P450 Cancer
    CYP450-IN-1 (compound 2e) is a potent inhibitor of CYP450 .
    CYP450-IN-1
  • HY-135281
    CYP11B2-IN-1

    		Cytochrome P450 Cardiovascular Disease
    CYP11B2-IN-1 is a CYP11B2 inhibitor with an IC50 of 2.3 nM. CYP11B2-IN-1 inhibits CYP11B1 with an IC50 of 142 nM .
    CYP11B2-IN-1
  • HY-151140
    CYP11B1-IN-2

    		Cytochrome P450 Others
    CYP11B1-IN-2 (compound 7aa) is an orally active, potent and selective CYP11B1 inhibitor, with IC50 values of 9 nM and 25 nM for human CYP11B1 and rat CYP11B1, respectively. CYP11B1-IN-2 can be used for the research of diseases caused by excessive cortisol .
    CYP11B1-IN-2
  • HY-150580
    CYP3A4-IN-2

    		Cytochrome P450 Inflammation/Immunology Cancer
    CYP3A4-IN-2 is a specific inhibitor of cytochrome P450 3A4 (CYP3A4) with the IC50 value of 0.055 μM. CYP3A4-IN-2 is a ritonavir analogue with increased hydrophobicity of the R2 side group and stronger inhibitory effect compared to ritonavir. CYP3A4-IN-2 can be used as an antiviral agent and immunosuppressants .
    CYP3A4-IN-2
  • HY-175836
    CYP1B1-IN-12

    		Cytochrome P450 Apoptosis Cancer
    CYP1B1-IN-12 is a selective cytochrome P450 1B1 (CYP1B1) inhibitor with an IC50 of 6.05 nM. CYP1B1-IN-12 demonstrates remarkable selectivity, exceeding 1600-fold and 16,000-fold over CYP1A1 and CYP1A2, respectively. CYP1B1-IN-12 can enhance Paclitaxel (HY-B0015)-mediated apoptosis and restore Paclitaxel sensitivity in A549/Taxol-resistant cells. CYP1B1-IN-12 can inhibit the epithelial-mesenchymal transition process and reduce cells migration and invasion. CYP1B1-IN-12 can be used for the research of cancer, such as non-small cell lung cancer (NSCLC) .
    CYP1B1-IN-12
  • HY-146177
    CYP3A4 enzyme-IN-1

    		Bacterial Cytochrome P450 Infection
    CYP3A4 enzyme-IN-1 (compound 59) is a potent antibacterial agent, with a MIC of 1 μg/mL for MRSA. CYP3A4 enzyme-IN-1 exhibits low to moderate inhibitory effects on CYP1A2, CYP2E1, CYP2D6, and CYP3A4 enzymes .
    CYP3A4 enzyme-IN-1
  • HY-175345
    CYP3A4-IN-5

    		Parasite Infection
    CYP3A4-IN-5 (Compound 5p) is a potent Leishmania major pteridine reductase 1 (Lm PTR1) inhibitor (IC50=12.77 µM). CYP3A4-IN-5 is promising for research of parasite infection .
    CYP3A4-IN-5
  • HY-152196
    CYP1B1-IN-5

    		Cytochrome P450 Cancer
    CYP1B1-IN-5 (Compound 6q) is a potent and selective cytochrome P450 1B1 (CYP1B1) inhibitor with an IC50 of 4.7 nM .
    CYP1B1-IN-5
  • HY-155456
    CYP2A6-IN-1

    		Cytochrome P450 Metabolic Disease
    CD-6 is a flavonoid CYP2A6 inhibitor (IC50: 1.566 μM). CYP2A6 inhibits the metabolism of nicotine to cotinine, resulting in an increase in the amount of nicotine available in the blood, leading to increased smoking behavior. CD-6 mediates CYP2A6 inhibition and can be used in research on smoking cessation or smoking-related diseases .
    CYP2A6-IN-1
  • HY-174425
    CYP1B1-IN-9

    		Cytochrome P450 Cancer
    CYP1B1-IN-9 is a highly selective and competitive CYP1B1 Inhibitor with IC50 values of 1.48 nM, > 100 μM, and > 80 μM for CYP1B1, CYP1A1, and CYP1A2, respectively. CYP1B1-IN-9 significantly inhibits the migration and invasion of A549/T cells. CYP1B1-IN-9 has the ability to resensitize Paclitaxel (HY-B0015)-resistant cells, and good metabolic stability and safety, and shows favorable pharmacokinetic parameters. CYP1B1-IN-9 can be used for the study of tumor-drug resistance .
    CYP1B1-IN-9
  • HY-151253
    CYP2C1/CYP2C19-IN-2

    		Cytochrome P450 Virus Protease Infection
    CYP2C1/CYP2C19-IN-2 (compound 21d) is a potent CYP2C9/CYP2C19 inhibitor, possessing no hepatotoxicity and ames toxicity. CYP2C1/CYP2C19-IN-2 can be used in study of anti-ZIKV .
    CYP2C1/CYP2C19-IN-2
  • HY-155493
    CYP19A1/CYP11B2-IN-1

    		Cytochrome P450 Cancer
    CYP19A1/CYP11B2-IN-1 (Compound X21) is a potent and selective aromatase and aldosterone synthase dual inhibitor with IC50s of 2.3 nM and 29 nM for aromatase (CYP19A1) and aldosterone synthase (CYP11B2), respectively. CYP19A1/CYP11B2-IN-1 has excellent antiproliferative and pro-apoptotic activity against the cancer cell. CYP19A1/CYP11B2-IN-1 can be used for research of breast cancer .
    CYP19A1/CYP11B2-IN-1
  • HY-149770
    CYP4A11/CYP4F2-IN-2

    		Cytochrome P450 Metabolic Disease
    CYP4A11/CYP4F2-IN-2 (compound 15) is an orally available inhibitor of CYP4A11/4F2 with IC50s of 120 nM and 220 nM, respectively. CYP4A11/CYP4F2-IN-2 inhibits 20-HETE production in rat kidney and has potential inhibitory effects on diabetic nephropathy and autosomal dominant polycystic kidney disease .
    CYP4A11/CYP4F2-IN-2
  • HY-179270
    CYP51-IN-30

    		Fungal Cytochrome P450 Infection
    CYP51-IN-30 is a CYP51 inhibitor and fungicidal agent. CYP51-IN-30 inhibits CYP51 activity. CYP51-IN-30 displays potent fungicidal activity with an EC50 value of 2.97 mg/L against S. sclerotiorum .
    CYP51-IN-30
  • HY-174973
    CYP51-IN-26

    		Fungal Cytochrome P450 Infection
    CYP51-IN-26 is a CYP51 inhibitor with an IC50 value of approximately 0.40 μM. CYP51-IN-26 eradicates C. auris biofilms. CYP51-IN-26 demonstrates significantly improved intracellular uptake in an accumulation assay. CYP51-IN-26 protects against C. auris infection in both G. mellonella and D. melanogaster models. CYP51-IN-26 can be used for research on fungal infections .
    CYP51-IN-26
  • HY-176210
    CYP51-IN-24

    		Fungal Cytochrome P450 Infection
    CYP51-IN-24 (Compound 22) is a Sterol 14α-Demethylase (CYP51) inhibitor. CYP51-IN-24 exhibits potent inhibitory activity against wild-type and drug-resistant fungi. CYP51-IN-24 inhibits ergosterol biosynthesis by binding to the fungal CYP51 enzyme. CYP51-IN-24 can be used in research and drug development against drug-resistant fungal infections .
    CYP51-IN-24
  • HY-174394S
    CYP51-IN-25

    		Isotope-Labeled Compounds Fungal Cytochrome P450 Infection
    CYP51-IN-25 is a orally active broad spectrum antifungal agent with the MIC80 of 0.00625-0.05 μg/mL. is a CYP51-IN-25 is a deuterated compound with antibiotic properties. CYP51-IN-25 can inhibit the fungal CYP51 enzyme, block ergosterol synthesis, and disrupt cell membrane integrity. CYP51-IN-25 can be used for research on fungal infections.
    CYP51-IN-25
  • HY-162370
    CYP51-IN-16

    		Cytochrome P450 Infection Cancer
    CYP51-IN-16 (compound C6) is a phenylpyrimidine CYP51 inhibitor, and shows antifungal activity in in vitro. CYP51-IN-16 inhibits tumor cell growth .
    CYP51-IN-16
  • HY-174353
    CYP51-IN-22

    		Cytochrome P450 Fungal Infection
    CYP51-IN-22, the non-deuterated analog of CYP51-IN-23-d3 (HY-174353S), is a potent and broad-spectrum CYP51 inhibitor.CYP51-IN-22 inhibits Aspergillus fumigatum with a MIC80 of 1 μg/mL. CYP51-IN-22 can prevent fungal phase transformation and biofilm formation. CYP51-IN-22 exhibits anti-drug resistance activity and fungal activity, and shows excellent safety for cells and significant pharmacological activity in mice. CYP51-IN-22 can be used for the study of invasive fungal infections (IFIs) .
    CYP51-IN-22
  • HY-162784
    CYP51-IN-19

    		Fungal Cytochrome P450 Infection
    CYP51-IN-19 (compound C07) is a potent CYP51 inhibitor. CYP51-IN-19 stimulates reactive oxygen species (ROS) and exhibits potent fungicidal activity .
    CYP51-IN-19
  • HY-159585
    CYP51-IN-20

    		Cytochrome P450 Fungal Infection
    CYP51-IN-20 (compound 5b) is an inhibitor of CYP51 and has antifungal activity. CYP51-IN-20 has a significant inhibitory effect on Candida albicans ATCC 10231, downregulates ERG11 (Cyp51) gene expression, and significantly reduces the yeast-to-hyphae morphological transition. CYP51-IN-20 can synergize with Voriconazole (HY-76200) to occupy the entire CYP51 binding site and exert a synergistic inhibitory effect in the Glechoma moth model .
    CYP51-IN-20
  • HY-163571
    CYP51-IN-17

    		Fungal Cytochrome P450 Bacterial Infection
    CYP51-IN-17 (compound 7a) is a potent CYP51 inhibitor with an IC50 of 0.377 μg/mL. CYP51-IN-17 shows significant fungicidal activity against B. cinerea with an EC50 of 0.326 μg/mL .
    CYP51-IN-17
  • HY-163633
    CYP51-IN-18

    		Cytochrome P450 Fungal Bacterial Infection
    CYP51-IN-18 (compound 2l) is a potent CYP51 inhibitor with an IC50 of 0.219 μg/mL. CYP51-IN-18 shows significant fungicidal activity against B. cinerea with an EC50 of 0.369 μg/mL .
    CYP51-IN-18
  • HY-144643
    CYP51/HDAC-IN-1

    		Fungal HDAC Cytochrome P450 Inflammation/Immunology
    CYP51/HDAC-IN-1 is a potent, orally active CYP51/HDAC dual inhibitor. CYP51/HDAC-IN-1 inhibits important virulence factors and down-regulated resistance-associated genes. CYP51/HDAC-IN-1 exhibits potent therapeutic effects for both tropical candidiasis and cryptococcal meningitis .
    CYP51/HDAC-IN-1
  • HY-101516
    CYP17-IN-1

    		Cytochrome P450 Cancer
    CYP17-IN-1 (compound 9c) is a potent and orally active CYP17 inhibitor against rat and human CYP17 with IC50s of 15.8 and 20.1 nM .
    CYP17-IN-1
  • HY-157333
    CYP51-IN-15

    		Parasite Cytochrome P450 Infection Inflammation/Immunology
    CYP51-IN-15 (9B) is a BBB penetrated Naegleria fowleri-specific CYP51 inhibitor, with an EC50 of 1.5 μM .
    CYP51-IN-15
  • HY-136764
    CYP51-IN-14

    		Fungal Infection
    CYP51-IN-2 (compound 1n), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80 of 1 μg/mL for Microsporum gypseum and Candida albicans .
    CYP51-IN-14
  • HY-136759
    CYP51-IN-9

    		Fungal Infection
    CYP51-IN-2 (compound 1i), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80 of 62.5 for Microsporum gypseum and Candida albicans .
    CYP51-IN-9
  • HY-136762
    CYP51-IN-12

    		Fungal Infection
    CYP51-IN-2 (compound 1l), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80 of 15.6 ng/mL for Microsporum gypseum and Candida albicans .
    CYP51-IN-12
  • HY-136754
    CYP51-IN-4

    		Fungal Infection
    CYP51-IN-2 (compound 1d), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80 of 15.6 ng/mL for Microsporum gypseum and Candida albicans .
    CYP51-IN-4
  • HY-148595
    CYP1A1-IN-2

    		Cytochrome P450 Cancer
    CYP1A1-IN-2 (Compound 14) is a competitive inhibitor of CYP1A1 (Ki: 1.4 μM). CYP1A1-IN-2 exhibits potent antimitotic activity and arrests cell in the G2/M phase. CYP1A1-IN-2 disrupts the microtubule and the cytoskeleton in CYP1A1-expressing breast cancer cells .
    CYP1A1-IN-2
  • HY-152079
    CYP1B1-IN-3

    		Cytochrome P450 Cancer
    CYP1B1-IN-3 is a potent and selective CYP1B1 inhibitor with IC50 values of 6.6, 347.3, >10000 nM for CYP1B1, CYP1A1, CYP1A2, respectively. CYP1B1-IN-3 inhibits cell migration and invasion. CYP1B1-IN-3 inhibits P-gp, AKT/ERK, FAK/SRC, and EMT pathways .
    CYP1B1-IN-3
  • HY-173279
    CYP19A1-IN-1

    		Cytochrome P450 Endocrinology
    CYP19A1-IN-1 (Compound 9) is a CYP19A1 inhibitor with an IC50 of 271 nM. CYP19A1-IN-1 inhibits the activity of converting androgens to estrogens by binding to CYP19A1. CYP19A1-IN-1 can be used in the research of sex hormone-related diseases such as estrogen-dependent breast cancer .
    CYP19A1-IN-1
  • HY-136763
    CYP51-IN-13

    		Fungal Infection
    CYP51-IN-2 (compound 1m), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80s of 62.5 and 250 ng/mL for Microsporum gypseum and Candida albicans, respectively .
    CYP51-IN-13
  • HY-136758
    CYP51-IN-8

    		Fungal Infection
    CYP51-IN-2 (compound 1h), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80s of 15.6 and 62.5 ng/mL for Microsporum gypseum and Candida albicans, respectively .
    CYP51-IN-8

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: